GlassScriptPhysician profile
Mark Jerome Anderson
NPI 1043236177
$600.60
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $58.12 · 2021: $31.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $142.26 | 2019-2020 | |
| Pfizer INC. | $135.14 | 2019 | |
| Janssen Biotech, INC. | $53.66 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $48.81 | 2019-2020 | |
| Boston Scientific Corporation | $47.99 | 2019-2020 | |
| Teleflex Medical Incorporated | $31.02 | 2021 | |
| Medtronic USA, INC. | $26.08 | 2019 | |
| 180 Medical, INC. | $24.21 | 2019 | |
| Blue Earth Diagnostics | $24.02 | 2019 | |
| Amgen INC. | $20.93 | 2019 | |
| Smith+Nephew, INC. | $18.32 | 2019 | |
| Coloplast Corp | $14.12 | 2019 | |
| Therapeuticsmd, INC. | $14.04 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.